Source link : https://www.newshealth.biz/health-news/fda-oks-first-drug-targeting-nrg1-gene-fusion-in-pancreatic-lung-cancers/
The FDA granted accelerated approval to the bispecific antibody zenocutuzumab (Bizengri) for NRG1 gene fusion-positive pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) on Wednesday. The approval stipulates use in advanced, unresectable, or metastatic disease that progressed on prior systemic therapy. Zenocutuzumab is the first approved therapy for NSCLC or pancreatic adenocarcinoma harboring an NRG1 […]
Author : News Health
Publish date : 2024-12-04 22:27:31
Copyright for syndicated content belongs to the linked Source.
inHealth